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BACKGROUND: OCT3/4 (POU5F1) is an established diagnostic immunohistochemical marker for specific histological variants of human
malignant germ cell tumours (GCTs), including the seminomatous types and the stem cell component of non-seminomas, known as
embryonal carcinoma. OCT3/4 is crucial for the regulation of pluripotency and the self-renewal of normal embryonic stem- and germ
cells. Detection of expression of this transcription factor is complicated by the existence of multiple pseudogenes and isoforms.
Various claims have been made about OCT3/4 expression in non-GCTs, possibly related to using nonspecific detection methods.
False-positive findings undermine the applicability of OCT3/4 as a specific diagnostic tool in a clinical setting. In addition, false-positive
findings could result in misinterpretation of pluripotency regulation in solid somatic cancers and their stem cells. Of the three
identified isoforms – OCT4A, OCT4B and OCT4B1 – only OCT4A proved to regulate pluripotency. Up until now, no convincing
nuclear OCT4A protein expression has been shown in somatic cancers or tissues.
METHODS: This study investigates expression of the various OCT3/4 isoforms in GCTs (both differentiated and undifferentiated) and
somatic (non-germ cell) cancers, including representative cell lines and xenografts.
RESULTS: Using specific methods, OCT4A and OCT4B1 are shown to be preferentially expressed in undifferentiated GCTs. The OCT4B
variant shows no difference in expression between GCTs (either differentiated or undifferentiated) and somatic cancers. In spite of
the presence of OCT4A mRNA in somatic cancer-derived cell lines, no OCT3/4 protein is detected. Significant positive correlations
between all isoforms of OCT3/4 were identified in both tumours with and without a known stem cell component, possibly indicating
synergistic roles of these isoforms.
CONCLUSION: This study confirms that OCT4A protein only appears in seminomatous GCTs, embryonal carcinoma and
representative cell lines. Furthermore, it emphasises that in order to correctly assess the presence of functional OCT3/4, both isoform
specific mRNA and protein detection are required.
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OCT3/4 (also known as POU5F1) is a well-known marker for
pluripotent stem cells, both physiologically and artificially induced
(Pesce and Scholer, 2000; Wang and Dai, 2010). In addition, it is
also expressed in primordial germ cells (PGCs) (Pesce and Scholer,
2000), the stem cell of gametogenesis later in life. OCT3/4 is a
transcription factor involved in self-renewal and pluripotency
(Niwa et al, 2000; Pesce and Scholer, 2001), and might counteract
apoptosis in PGCs (Kehler et al, 2004). During further develop-
ment (differentiation/maturation) of these types of embryonic
cells, expression is downregulated and finally lost in the
differentiated derivatives. Owing to this specific pattern of
expression during embryogenesis, which is retained during the
process of malignant transformation, OCT3/4 is an established and
highly informative diagnostic marker for defined types of
malignant germ cell tumours (GCTs), especially those of the
seminomatous cell type (seminoma (SE), dysgerminoma and
germinoma) and embryonal carcinoma (Looijenga et al, 2003;
de Jong and Looijenga, 2006; Cheng et al, 2007; Looijenga, 2009).
The OCT3/4 gene is located on human chromosome 6 band p21
and consists of five exons (Takeda et al, 1992; Krishnan et al,
1995). It encodes a protein belonging to the family of octamer-
binding proteins that specifically binds to the conserved ATTTTG-
CAT motive in transcriptional control elements of genes. This
sequence is recognised by the highly charged POU domain of the
OCT3/4 protein, explaining its alternative name. The POU domain
consists of two subdomains: a C-terminal homeodomain and an N-
terminal POU-specific region separated by a short non-conserved
linker (Sturm and Herr, 1988).
Various investigations of OCT3/4 expression are reported, both
on mRNA and protein level. Most are complicated by the existence
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of pseudogenes and splice variants (isoforms) (de Jong and
Looijenga, 2006; Liedtke et al, 2008; Wang and Dai, 2010), possibly
leading to findings of false-positive expression. Till date, five
OCT3/4 pseudogenes have been identified. These will be amplified
by most of the published primer sets, owing to their high sequence
similarity to OCT4A (Pain et al, 2005; Suo et al, 2005). However,
proper DNase pre-treatment of the samples will exclude this
technical artefact, which is a rather simple and straightforward
step to include in the experimental setup.
In addition, three splice variants (isoforms) of OCT3/4 have
been identified (Wang and Dai, 2010). The best-known isoform is
referred to as OCT4A. This variant is reported to be stem cell-
specific, whereas the function(s) of the other two variants, that is,
OCT4B and OCT4B1, are still under investigation (Gao et al, 2010;
Wang and Dai, 2010; Asadi et al, 2011). However, it has been
demonstrated that OCT4B is unable to activate or repress
transcription of known OCT4A-responsive genes (Lee et al,
2006). Therefore, OCT4B seems unlikely to be directly involved
in transcriptional regulation of pluripotency and self-renewal.
OCT4B1 on the other hand, has recently been suggested to have a
role in both regulation of pluripotency (Atlasi et al, 2008;
Papamichos et al, 2009; Asadi et al, 2011) and OCT4B-mediated
functions (Gao et al, 2010).
As indicated, OCT3/4 has mainly been linked to pluripotency,
for which it is a well-known and established marker. Pluripotency
refers to the capacity of a (embryonic) stem cell to generate all
different tissues (endo-, ecto- and mesodermal differentiation).
Indeed, differentiation induction is associated with downregula-
tion of OCT3/4 (Botquin et al, 1998; Velkey and O’Shea, 2003; Hay
et al, 2004; Matin et al, 2004; Zaehres and Scholer, 2007). The other
way around, OCT3/4 downregulation results in loss of stem cells
and induction of differentiation (Niwa et al, 2000). A high-
throughput immunohistochemical screen of many different types
of human cancers demonstrated that OCT3/4 is a specific and
highly informative diagnostic marker for seminomatous tumours,
which are the malignant counterparts of PGCs/gonocytes, as well
as embryonal carcinomas, the stem cell component of non-
seminomas (Looijenga et al, 2003; de Jong et al, 2005). This
observation is confirmed by multiple independent studies, as
reviewed before (Looijenga, 2009). The overall findings resulted in
the conclusion that OCT3/4 is an excellent, and currently
successfully used, diagnostic marker for the detection of undiffer-
entiated variants of so-called type II GCTs (UNDIF-GCTs¼ SE or
dysgerminoma/germinoma, and the stem cell component of non-
seminoma (NS, specifically embryonal carcinoma)), as well as their
precursor stages (carcinoma in situ of the testis (CIS) and
gonadoblastoma of dysgenetic gonads) (Looijenga et al, 2003;
de Jong et al, 2005, 2008b; de Jong and Looijenga, 2006; Cheng
et al, 2007). Most recently, OCT3/4 protein detection has been used
as a diagnostic tool for the non-invasive diagnosis of CIS (van
Casteren et al, 2008).
In non-GCTs (N-GCTs), a highly heterogeneous expression
pattern of OCT3/4, both mRNA and protein, is reported. This
might be due to the use of nonspecific primers detecting other
isoforms, improper DNAse pretreatment (resulting in amplifica-
tion of pseudogenes) and incorrect interpretation of immuno-
histochemical stainings. The results of the various articles (Ezeh
et al, 2005; Tai et al, 2005; Atlasi et al, 2007; Lengner et al, 2007;
Chen et al, 2008; Lai et al, 2009; Sotomayor et al, 2009) to whether
or not there is expression of (functional) OCT3/4 in solid cancers
are therefore inconclusive. To further investigate this issue, the
current study was undertaken. It investigates expression of the
different isoforms of OCT3/4 mRNAs and protein in various types
of solid cancers: undifferentiated GCTs (UNDIF-GCTs) and GCTs
without an embryonic stem cell component (DIF-GCTs¼ yolk sac
tumours and teratomas) as well as N-GCTs. Also, representative
cell lines (CL) of UNDIF-GCT and N-GCT are included.
MATERIALS AND METHODS
Materials
The cell lines and tumour samples included in this study are
indicated in Table 1. All samples/cell lines were obtained from
different Departments in the Josephine Nefkens Institute (Erasmus
MC-University Medical Center, the Netherlands). The prostate
carcinoma cell lines and xenografts are extensively reviewed
elsewhere (van Weerden et al, 1996; Marques et al, 2006). This also
goes for the GCT-CLs (Andrews et al, 1996; de Jong et al, 2007,
2008a).
RNA isolation
High-quality total RNA was extracted from the above mentioned
cell lines and tumour samples using TRIzol Reagent (Invitrogen,
Table 1 Samples and cell lines included in the study
Group Subgroup Cell lines/No. of tumour samples
Undifferentiated GCT cell lines (UNDIF-GCT-CL) Seminoma
Embryonal carcinoma
Other
TCam-2
TERA1, NCCIT, NT2
JKT-1
Non GCT cell lines (N-GCT-CL) Oesophaguscarcinoma ESO26, ESO51, I2425
Cervixcarcinoma HeLa
Lungcarcinoma H460
Coloncarcinoma H716, HCT116, SW620
Prostatecarcinoma Cell lines: LNCaP, 22Rv1, VCaP, LAPC-4, MDA PCa 2b
Xenografts: PC324, PC329, PC339, PC346B, PC346C, PC374, PC133,
PC82, PC135, PC295, PC310
Breastcarcinoma MDA175, ZR75
Undifferentiated GCTs (UNDIF-GCT) Seminoma (SE) 5
Embryonal Carcinoma (EC) 4
Differentiated GCTs (DIF-GCT) Teratoma (TE) 5
Yolk sac tumour 1
Non-GCT (N-GCT) Bladdercarcinoma 5
Lungcarcinoma 4
Ovariancarcinoma 5
Prostatecarcinoma 5
Rectalcarcinoma 4
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Breda, The Netherlands) according to the manufacturer’s instruc-
tions. Samples were pretreated with DNase I, checked for residual
DNA contamination by PCR, after which cDNA synthesis was
performed as described before (Looijenga et al, 2006; de Jong et al,
2008a). For each sample, a no-reverse transcription control was
used, and HPRT was used as reference level of expression.
Quantitative PCR was performed using the Real-Time PCR HT7900
(Applied Biosystems, Foster City, CA, USA). Sequences for the
OCT3/4 splice variant specific primers were as described before
(Atlasi et al, 2008; de Jong et al, 2008a). These are highly specific
for the different isoforms and even discriminate between OCT4A
and its pseudogenes. The following forward (F) and reverse (R)
primers were used (annotation between brackets¼ annotation
from (Atlasi et al, 2008)): HPRT: HPRT244-exon2-F, 50-AATTATGG
ACAGGACTGAACGTC-3 0; HPRT243-exon3-R, 50-CGTGGGGTCCTT
TTCACCAGCAAG-30. OCT4A: OCT4A-F (OCT4-AF) 50-CTTCTCG
CCCCCTCCAGGT-3 0; OCT4A-R (OCT4-RB1) 50-AAATAGAACCCC
CAGGGTGAGC-3 0. OCT4B: OCT4B-F (OCT4-FB) 50-AGACTATTC
CTTGGGGCCACAC-30; OCT4B-R (OCT4-RB5) 50-GGCTGAAT
ACCTTCCCAAATAGA-3. OCT4B1: OCT4B-F (OCT4-FB), 50-AGAC
TATTCCTTGGGGCCACAC-30; OCT4B1-R (OCT-RB4) 50-CCCCCTG
TCCCCCATTCCTA-30. The localisation of the different primers is
depicted in Figure 1. The efficiency and specificity of these primers
was extensively tested before (Atlasi et al, 2008). The specificity for
human RNA is proven by the absence of any OCT4A/B/B1 expression
in most of the xenografts, specifically in PC82, which has a large
stromal component. Quantitative values were obtained from the Ct.
OCT3/4mRNAs (A, B and B1) were quantified with relative to HPRT
(OCT3/4 mRNA¼ 2 (mean Ct HPRTmean Ct OCT3/4 (A, B or B1)) as
described before (Livak and Schmittgen, 2001). The OCT4B1 PCR-
products were sequenced using OCT4B1-F and a primer in exon 5
(OCT4B1-R2: (OCT4-RB3) 50-CCCCCTGTCCCCCATTCCTA-30) to
verify the nature of this splice variant. MicroRNA expression was
measured as described previously (Gillis et al, 2007).
Immunohistochemistry
Immunohistochemistry was performed on paraffin-embedded
tissue sections of 4 mm thickness. Endogenous peroxidase and
biotin were blocked. A mouse monoclonal antibody directly
against OCT3/4 was used to detect OCT3/4 protein ((1 : 350;
SC5279), Santa Cruz, Heidelberg, Germany), which recognises
amino acids 1–134 of the protein and therefore recognises OCT4A
more specifically than the polyclonal antibody. Expression of
OCT3/4 protein was double checked for most samples using a
polyclonal antibody ((1 : 350; SC8629), Santa Cruz). Previously (de
Jong et al, 2005), a similar specificity and sensitivity of these
antibodies in GCT tumour diagnostics has been shown, but did not
yet differentiate between the different OCT3/4 isoforms. The
proteins of the different isoforms only differ at their N terminus.
Therefore, the monoclonal antibody is specific for OCT4A.
However, strong similarities still exist in these regions between
OCT4A and OCT3/4 pseudogenes (Atlasi et al, 2008; Wang and
Dai, 2010). Slides were incubated as described earlier (Looijenga
et al, 2003). For different tissues and cell lines known positive
controls were used to verify tissue integrity. The following
antibodies were used: E-cadherin (1 : 200; clone nch-38, DAKO,
Glostrup, Denmark), Ki-67 (1 : 50; clone BIB-1, code M7240,
DAKO), AFP (1 : 100; code A008, DAKO), Pankeratin (1 : 400; Cat
#MS-743-P, Neomarkers, Fremont, CA, USA), ERG (1 : 100; clone
EPR3864, Epitomics, Burlingame, CA, USA), TTF1 (1:200; Cat
#MS-699-P, Neomarkers), SOX2 (1 : 250; AF2018, R&D systems,
Oxon, UK), NANOG (1 : 400; AF1979, R&D systems), ER (1 : 50);
clone 1D5, Neomarkers).
Statistics
Differences in gene expression between the groups were evaluated
using the Mann–Whitney U-test, using VassarStats (faculty.vassar.
edu). A P-value o0.05 was considered as statistically significant.
Correlation analysis was performed by calculating the Pearson
correlation coefficient using SPSS 15.0.1 (IBM Corp., Armonk, NY,
USA). SPSS was also used to design the logistic regression model
predicting the presence of a malignant GCT stem cell component
based on mRNA expression of the three OCT3/4 variants.
RESULTS
General
Isoform-specific expression of the various isoforms OCT4A,
OCT4B and OCT4B1 was analysed in a series of UNDIF-GCTs
and DIF-GCTs as well as N-GCTs. Moreover, expression of these
isoforms was also investigated in a panel of cell lines (both GCT-CL
(de Jong et al, 2007, 2008a) and N-GCT-CL, the latter including the
prostate xenografts). For this purpose, a highly specific set of
verified primer pairs was used (see Materials and Methods and
Figure 1 for details). The primer pair used to identify OCT4A was
specifically designed to avoid false-positive results caused by
sequence-based similarities between the OCT4A transcripts and
OCT3/4 pseudogenes (Atlasi et al, 2008; de Jong et al, 2008a). The
obtained results will be discussed in the following paragraphs for
each OCT4A, OCT4B and OCT4B1 separately. Subsequently,
correlations between the different variants and association with
the presence of a malignant GCT stem cell component were
investigated. Finally protein expression will be discussed and
correlated to mRNA expression.
OCT4A mRNA expression
OCT4A was significantly higher expressed in UNDIF-GCTs than in
DIF-GCTs and N-GCTs (Figure 2A, Table 2). There was no
significant difference between DIF-GCTs and N-GCTs. An overall
higher level of expression was observed in the seminomas when
compared with embryonal carcinomas (Figure 2B, Table 2). The
DIF-GCTs, that is, yolk sac tumours and teratomas, consistently
showed virtually no expression of OCT4A. In the N-GCT group,
tumours showed no or very low OCT4A expression (bladder-,
prostate-, breast-, lung-, ovarian- and renal carcinomas, respec-
tively) (Figure 2C, Table 2).
OCT4A was significantly higher expressed in GCT-CLs than in
N-GCT-CLs (P¼ 0.02) (Figure 3). All proven GCT-CLs consistently
showed high-expression levels of OCT4A. Expression of OCT4A is
known to be absent in JKT-1, a not yet fully classified cell line,
suspected to be germ cell-like, although not related to a seminoma
(de Jong et al, 2007). Of note is that a few N-GCT-CLs showed a
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Exon 1b
Exon 2
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Exon 3
Exon 3
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Figure 1 mRNA structure of the different OCT3/4 splice variants. All
OCT3/4 splice variants have a similar 30 ends but differ in their 50 start (i.e.,
exons 1a and 1b). Moreover OCT4B1 includes a previously identified
intronic region now named exon 2b. For a detailed discussion see Atlasi
et al, 2008. Red arrows indicate forward (F) and reverse (R) primers
from (Atlasi et al, 2008) used in the reverse transcription–polymerase
chain reaction to specifically identify the different OCT3/4 splice variants.
Green arrow denotes a specific reverse primer used to sequence OCT4B1.
The colour reproduction of this figure is available at the British Journal of
Cancer online.
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relatively high OCT4A expression level, defined as at least a ratio of
1.0 when compared with HPRT. However, most of the GCT-CLs
showed expression levels of 410. Cell lines with ratios of at least
1.0 included ESO51, HeLa, H460 and H716B. Ratios between 0.25
and 1.0 were found in one prostate and one mamma carcinoma cell
line (22Rv1 and MDA175). All other N-GCT-CLs showed a low
level or absence of OCT4A expression (Figure 3).
OCT4B mRNA expression
OCT4B was expressed at equally low levels in UNDIF-GCTs and
DIF-GCTs (Figure 2A, Table 2). No significant difference was
detected between UNDIF-GCTs or DIF-GCTs and N-GCTs
(Figure 2A, Table 2). Among the UNDIF-GCTs, seminomas
expressed a low level of OCT4B, whereas OCT4B was virtually
undetectable in embryonal carcinoma. The DIF-GCTs showed low
expression in teratomas and practically absence of OCT4B in yolk
sac tumours (Figure 2B, Table 2). Expression levels of OCT4B were
highly variable within the N-GCT group. The bladder carcinoma
samples showed the highest level of expression, which was rather
similar between different samples. The ovarian and renal
carcinomas showed an intermediate level of expression, because
of a number of high outliers within these groups. Almost no
expression was found in lung, prostate and breast cancer samples
(Figure 2C, Table 2).
The cell lines showed a highly variable expression of OCT4B
(Figure 3). All UNDIF-GCT-CLs showed no or a very low level of
OCT4B mRNA. No significant difference between N-GCT-CLs and
UNDIF-GCT-CLs was detected (P¼ 0.76). Most of the cell lines
showed very low levels or absence of OCT4B expression. Relatively
high levels of OCT4B were detected in HeLa, as well as in H716 and
PC329. Moderate levels were detected in ESO51, VCaP and PC374
(Figure 3).
OCT4B1 mRNA expression
UNDIF-GCTs showed a significantly higher level of expression of
OCT4B1 than N-GCTs and DIF-GCTs (Figure 2A, Table 2).
DIF-GCTs and N-GCTs showed no significant difference
(Figure 2A, Table 2). Expression in the UNDIF-GCT group was
high in seminoma and intermediate in embryonal carcinoma
(Figure 2B, Table 2). Regarding DIF-GCTs, teratomas expressed
intermediate levels of OCT4B1, whereas expression in yolk sac
tumours was low (Figure 2B). Overall, expression of OCT4B1 was
Table 2 Comparison of OCT4A/B/B1 expression in tumour samples
MRNA
Protein
OCT4A OCT4B OCT4B1
UNDIF-GCT High Low High Nuclear
SE High Low High Nuclear
EC Intermediate Low Intermediate Nuclear
DIF-GCT Low Low Intermediate —
YS Low Low Low —
TE Low Low Intermediate —
N-GCT Low Low Low —
Bladdercarcinoma Low High Intermediate —
Lungcarcinoma Low Low Intermediate —
Ovariancarcinoma Low Intermediate Low —
Prostatecarcinoma Low Low Low —
Breastcarcinoma Low Low Low —
Renal cell carcinoma Low Intermediate Low —
Comparison between groups
UNDIF-GCT vs DIF-GCT m NS m
UNDIF-GCT vs N-GCT m NS m
DIF-GCT vs N-GCT NS NS NS
mRNA expression is scored as high (red, 2^-dCt4 1), intermediate (black, 2^-dCt
0.25-1) or low (green, 2^-dCt o0.25). The main tumour groups are tested for
differential expression of the three OCT3/4 variants: NS¼ not significant, green arrow
means relative overexpression of X in X vs Y comparison. P-values: OCT4A (UNDIF-
GCT vs DIF-GCT P¼ 0.02, UNIF-GCT vs N-GCT Po0.01, DIF-GCT vs N-GCT
P¼ 0.50); OCT4B (UNDIF-GCT vs DIF-GCT P¼ 0.95, UNDIF-GCT vs N-GCT
P¼ 0.89, DIF-GCT vs N-GCT P¼ 0.89); OCT4B1 (UNDIF-GCT vs DIF-GCT
P¼ 0.04, UNDIF-GCT vs N-GCT Po0.01, DIF-GCT vs N-GCT P¼ 0.39). Protein
expression is scored as positive (red, nuclear or cytoplasmic) or negative (, green)
for absent or non-specific background staining. Staining with the monoclonal antibody
was used for scoring. The colour reproduction of this figure is available at the British
Journal of Cancer online.
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Figure 2 Expression patterns of OCT4A, OCT4B and OCT4B1 in
UNDIF-GCT, DIF-GCT and N-GCT. x Axis: tumour samples/groups (see
Materials and Methods). y Axis: 2^dCt (normalised to HPRT). Error bars
depict s.e.m.: variation within the groups (A–C). (A) Average expression
for UNDIF-GCT, DIF-GCT and N-GCT groups. (B) Average expression
for the UNDIF-GCT and DIF-GCT samples grouped per tumour type
(SE¼ seminoma; EC¼ embryonal carcinoma; YS¼ yolk sac tumour;
TE¼ teratoma). (C) Average expression for the N-GCT samples grouped
per tumour type. CA¼ carcinoma.
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low in N-GCTs. Bladder carcinomas showed, just as in the case of
OCT4B, a relatively high expression level of OCT4B1 when
compared with other types of N-GCTs (Figure 2C).
Levels of OCT4B1 expression varied between the cell lines. No
significant difference between UNDIF-GCT-CLs and N-GCT-CLs was
detected (P¼ 0.92). High expression was observed in TCam-2, ESO51,
HeLa, H716, 22Rv1, PC329 and PC374. Moreover, intermediate
expression levels were present in NCCIT, ESO26, SW620, VCaP,
PC324, PC339, PC135 and PC295. In many cases (ESO51, SW620,
H716, VCaP, PC329, PC374), intermediate or high levels of OCT4B1
were combined with comparable levels of OCT4B (Figure 3).
During the sequencing process to confirm the PCR products for
the different splice variants, a consistent TC insertion was found in
exon 2B of OCT4B1, being a single nucleotide polymorphism
(SNP) (rs34631505). This SNP is located behind the stop codon
and therefore has no consequence at the protein level.
Correlation between mRNA expression of different OCT3/4
isoforms and association of specific isoform expression
and presence of a malignant germ cell component
When all samples were combined, OCT4A showed a strong
positive correlation with OCT4B1 and a less strong correlation
with OCT4B. OCT4B and OCT4B1 did not correlate significantly
(Table 3). However, when the samples were split into undiffer-
entiated (UNDIF-GCT) and differentiated tumours (DIF-GCTþ
N-GCT), strong, positive and highly significant correlations were
found between all OCT3/4 variants. Overall, the strength of the
correlation approached perfect positive correlation in the UNDIF-
GCT. In general, the correlations were less strong in the
differentiated tumours, but still highly significant and positive
(Table 3). In a binary logistic regression model, OCT4A and
OCT4B proved to be significant in predicting the presence of a
malignant GCT stem cell component. OCT4A was strongly
predictive for the presence a malignant GCT stem cell component
(b¼4.92, P¼ 0.045), whereas OCT4B proved to be suggestive for
the absence of such a component, but this association was less
strong (b¼1.28, P¼ 0.048).
Protein detection
Immunohistochemical staining of the various GCT samples and
cell lines was performed to assess OCT3/4 protein expression.
Clear nuclear staining of tumour cells was shown in UNDIF-GCTs.
No expression was detected in the DIF-GCT components or in the
N-GCT samples (Figure 4). In accordance with the findings in the
tumour samples, nuclear staining of tumour cells was shown in GCT-
CLs, while being absent in all N-GCT-CLs and xenografts. Both the
EC cell lines (NCCIT and NT2) and the SE cell line TCam-2 were
OCT3/4 positive. The nonspecific staining in the xenografts was
based on necrosis, and again no cytoplasmic or nuclear staining
was detected in these samples (Figure 5). Positive controls for all
samples prove that all samples were suitable for immunohisto-
chemistry (Supplementary Figures S1A, B and S4A) and HE
staining was used to assess tumour morphology (Supplementary
Figures S2A and B). Finally, a double check for OCT3/4 expression
was performed by staining the same tumour samples (Supplemen-
tary Figures S3A and B) and cell lines/xenografts (Supplementary
Figure S4B) with a second (polyclonal) antibody directed against
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Figure 3 Expression patterns of OCT4A, OCT4B and OCT4B1 in cell lines. (A) mRNA levels in all investigated cell lines, both of GCT origin (GCT-CL) and
non-GCT origin (N-GCT-CL). *¼ cervix carcinoma; **¼ lung carcinoma. x Axis: cell lines (see Materials and Methods) and corresponding tumour class.
y Axis: 2^dCt (normalised to HPRT). (B) Interpretation of the expression of OCT3/4 isoforms relative to HPRT. mRNA expression is scored as high (red, 2^-
dCt41), intermediate (black, 2^-dCt 0.25-1) or low (green, 2^-dCto0.25). CA¼ carcinoma. The colour reproduction of this figure is available at the British
Journal of Cancer online.
Table 3 Correlation between OCT4A/B/B1 mRNA expression in
tumour samples
All UNDIF-GCT DIF-GCT+N-GCT
OCT4B OCT4B1 OCT4B OCT4B1 OCT4B OCT4B1
OCT4A + +++ +++ +++ ++ +++
OCT4B NS +++ ++
Correlation was assessed using the Pearson correlation coefficient on the mRNA
expression data of all tumour samples, the UNDIF-GCT group and the differentiated
tumours (DIF-GCT and N-GCT). LEGEND: +++¼ r40.75; ++¼
r40.5; +¼ ro0.5; NS¼ not significant. CORRELATION COEFICIENT/SIGNIFI-
CANCE: All: rOCT4A,OCT4B¼ 0.37 (P¼ 0.01), rOCT4A,OCT4B1¼ 0.89 (Po0.01),
rOCT4B,OCT4B1¼ 0.12 (P¼ 0.44). UNDIF-GCT: rOCT4A,OCT4B¼ 0.98 (Po0.01),
rOCT4A,OCT4B1¼ 1.00 (Po0.01), rOCT4B,OCT4B1¼ 0.99 (Po0.01). DIF-GCT+N-GCT:
rOCT4A,OCT4B¼ 0.63 (Po0.01), rOCT4A,OCT4B1¼ 0.97 (Po0.01), rOCT4B,OCT4B1¼ 0.68
(Po0.01).
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OCT3/4. This confirmed our findings that OCT3/4 protein expression
is specific to UNDIF-GCTs and the related cell line models (GCT-CLs).
These data are completely in accordance with previously published
findings (Looijenga et al, 2003; de Jong et al, 2005).
DISCUSSION
Specificity: the pitfalls of pseudogenes and isoforms
Detection of OCT3/4 pseudogenes can and should be avoided by
sufficient DNAse pretreatment of the sample, because the
respective sequences might be amplified based on their high level
of similarity with the protein-encoding variant (OCT4A) and the
absence of introns. Therefore, their amplification in PCR might be
falsely interpreted as actual OCT4A expression, suggesting possible
translation into OCT4A protein. Moreover, specific PCR primer
pairs followed by antibody-based analysis should be used to detect
the different isoforms of OCT4 at the mRNA level and the presence
of protein (Liedtke et al, 2007; Atlasi et al, 2008; de Jong et al,
2008a; Sotomayor et al, 2009).
By using such a validated, isoform-specific primer pair setup,
this study shows that OCT4A is highly expressed in UNDIF-GCTs,
which are known to have a pluripotent stem cell component,
originating from PGCs/gonocytes (Oosterhuis and Looijenga, 2005;
Looijenga, 2009). DIF-GCTs and N-GCT show virtually no OCT4A
expression, which is in line with the notion that OCT4A is
UNDIF- GCT DIF-GCT
TE (1)
TE (2)
YS (1)
YS (2)
EC (1)SE (1)
SE (2) EC (2)
BLADDER CA (1)
BLADDER CA (2)
LUNG CA (1)
LUNG CA (2)
BREAST CA (1)
BREAST CA (2) PROSTATE CA (2)
RENAL CA (1)
RENAL CA (2)
OVARIAN CA (1)
OVARIAN CA (2)
PROSTATE CA (1)
N-GCT
A
B
Figure 4 Immunohistochemical detection of OCT3/4 expression in tumour samples. For each tumour type, two different samples are shown.
Magnification  100. (A) Protein expression of OCT3/4 in UNDIF-GCTs and DIF-GCTs. Shown are two seminomas (SEs), embryonal carcinomas (ECs),
yolk sac tumours (YSs) and teratomas (TEs), of which only the first two types are positive. (B) Protein expression of OCT3/4 in N-GCT tumour samples,
including two carcinomas of the bladder, lung, breast, ovary, prostate and kidney, respectively, all are negative. All samples were stained using an antibody
that is most specific for OCT4A (see Materials and Methods). The colour reproduction of this figure is available at the British Journal of Cancer online.
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ESO26 (OESOPHAGUS CA) ESO51 (OESOPHAGUS CA) I2425 (OESOPHAGUS CA)
HELA (CERVIX CA) H460 (LUNG CA)
ZR75 (BREAST CA)
H716 (COLON CA)
PC346C (PROSTATE CA)
HCT116 (COLON CA) VCaP (PROSTATE CA)
SW620 (COLON CA)
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PC374 (PROSTATE CA) PC135 (PROSTATE CA) PC324 (PROSTATE CA) PC82 (PROSTATE CA)
GCT-CL
N-GCT-CL
Figure 5 Immunohistochemical detection of OCT3/4 expression in cell lines and xenografts. Stained are the undifferentiated GCT-CLs NT2, NCCIT and
TCam-2, which are all positive. All somatic cancer cell lines (ESO26, ESO51, I2425, ZR75, HELA, H460, SW620, H716, HCT116, VCaP, 22Rv1, LAPC-4,
LNCaP) and xenografts (PC310, PC295, PC346C, PC374, PC135, PC324, PC82) are negative (some nonspecific staining of necrosis). All samples were
stained using an antibody that is most specific for OCT4A (see Materials and Methods). Magnification  200 GCT-CLs, 100N-GCT-CLs.
CA¼ carcinoma. The colour reproduction of this figure is available at the British Journal of Cancer online.
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responsible for formation of the protein involved in regulation of
pluripotency. In contrast, OCT4B is not differentially expressed
between the three groups, whereas OCT4B1 is expressed sig-
nificantly higher in the UNDIF-GCTs when compared with DIF-
GCTs and N-GCTs, as found for OCT4A. These results indeed
support the general consensus that OCT4A is the marker for stem
cell populations in GCTs, and a similar specificity could be
suggested for the OCT4B1 variant. However, OCT3/4 protein is
only detected in GCTs and representative cell lines, also in this
study. No specific signal could be detected in any of somatic
cancers or cell lines investigated, irrespective of mRNA expression
pattern. Because OCT4A protein is the only one of the three
isoforms that directly regulates pluripotency, expression of this
protein is a prerequisite for any cell that uses OCT3/4 as a
regulator of pluripotency. Therefore, even specific mRNA detec-
tion of OCT3/4 isoforms does not yet conclusively prove the
applicability of OCT4A, OCT4B or OCT4B1 in the detection of
pluripotent cancer stem cells (see below) or somatic stem cells
without protein confirmation.
Functions of OCT3/4 isoforms
OCT3/4 is a known marker for pluripotency and has been shown to
have a role in regulation of pluripotency (Pesce and Scholer, 2000,
2001; Wang and Dai, 2010). Moreover, it is an important diagnostic
marker for specific types of GCTs (Looijenga et al, 2003; Oosterhuis
and Looijenga, 2005; de Jong et al, 2005; de Jong and Looijenga,
2006; Looijenga, 2009). Recently, investigations into the broader
applicability of OCT4 as a marker in (cancer) stem cell biology
showed that only OCT4A (and not OCT4B and OCT4B1) is specific
to stem cell (like) populations (Tai et al, 2005; Lengner et al, 2007;
Atlasi et al, 2008; Cantz et al, 2008; Sotomayor et al, 2009; Wang and
Dai, 2010). It has been shown that basic levels of OCT3/4 mRNA
(even OCT4A) and expression its pseudogenes, are detectable in
somatic (tumour) cells (Wang and Dai, 2010; Zhao et al, 2011).
However, OCT4A protein expression has so far never been
conclusively shown in non-pluripotent cells (Wang and Dai, 2010).
In addition, it has been described that OCT4A is primarily localised
in the nucleus, whereas OCT4B1 primarily resides in the cytoplasm.
OCT4B might have a role in stress response (Wang and Dai,
2010). The role of OCT4B1 is more elusive. It has been associated
with both pluripotency and tumourigenesis (via inhibition of
apoptosis and cell cycle deregulation) (Asadi et al, 2011). Also, a
recent report suggested OCT4B1 to be superior to OCT4A in the
detection of stemness, at least in human embryonic stem cells
(Papamichos et al, 2009). These results are mainly based on
statistical correlation and lack a biological explanation as to how
OCT4B1 contributes to pluripotency, as this variant cannot be
directly translated into a functional transcription factor (Atlasi
et al, 2008). Moreover, the presence of OCT4B1 expression in
cancer tissues, which consists of mainly differentiated tissue, is not
satisfactory linked to a specific hypothetical in situ population of
cancer stem cells. In contrast, Gao et al, 2010 conclude that
OCT4B1 can be alternatively spliced and subsequently be
translated into all OCT4B protein forms , linking OCT4B1 to
OCT4B-mediated functions like stress response.
The various OCT3/4 isoforms might also have an integrated
function as interchangeable decoys in microRNA (miR)-regulated
OCT3/4 protein expression. miRs, specifically miR-145 which
targets OCT3/4, have been suggested to have a role in the
regulation of pluripotency in general and OCT3/4 translation
specifically (Xu et al, 2009). Competitive miR binding has been
suggested as a biological function of pseudogenes (Poliseno et al,
2010). This function might also apply to alternative splice variants
that, such as the OCT3/4 variants, share their 30UTR. OCT4B and/
or OCT4B1 might prevent translation inhibition of OCT4A mRNA
in stem cell components of GCTs or the other way around in
differentiated GCTs or somatic cancer cells. The latter could
explain OCT4A mRNA expression without translation into
detectable protein in somatic cancer cells. This hypothesis is
supported by a correlation analysis on the OCT4A/B/B1 mRNA
expression data (Table 3). We showed strong correlations between
OCT4B and B1 (Table 3) (expected based on similar function (Gao
et al, 2010)) and OCT4A and B/B1 (strongest in UNDIF-GCT in
which OCT4A is active at the protein level). However, functional
studies are required to support this hypothesis.
Finally, individuals homozygous for a polymorphism at the
initiating codon of OCT3/4 (rs3130932) are not able to transcribe
OCT4B1, and are therefore lacking the putative encoding proteins
(Takeda et al, 1992; Hussain et al, 2008). Depending on race, minor
allele frequencies of 23–33% are reported (Hussain et al, 2008). So
far, no abnormalities have been found related to the absence of this
protein in these individuals, but it would be interesting to
investigate the relative frequency of this SNP in GCT patients,
specifically with respect to OCT3/4 (protein) expression, tumour
characteristics and clinical course.
OCT3/4 isoforms in (cancer) stem cells
Our results disprove the applicability of OCT3/4 mRNA (Tai et al,
2005) for the detection of pluripotent cells (possibly cancer stem
cells (Collins et al, 2005; Ricci-Vitiani et al, 2007)) in solid cancers.
Bladder carcinomas showed high mRNA expression of OCT4B and
OCT4B1, but no OCT4A. This explains earlier reports of high
nonspecific OCT4 expression in this type of cancer (Atlasi et al,
2007), but does not indicate the presence of OCT4A-positive
cancer stem cells. Moreover, our analysis identified no OCT4A
expression in prostate carcinoma, which has been reported before
(Sotomayor et al, 2009) using a specific primer set (Liedtke et al,
2007). In contrast, low, but detectable, levels of OCT4A mRNA
were found in lung-, ovary- and renal carcinoma samples. Also,
some of the studied cell lines showed OCT4A mRNA expression,
suggesting the presence of pluripotent cells in these cultures.
However, no OCT3/4 protein expression could be identified in any
of the N-GCT samples or N-GCT-CLs, using both monoclonal and
polyclonal antibodies. Also the ‘stem cells’ in cell lines do not
necessarily represent in vivo cancer stem cells, illustrated by the
absence of OCT4A mRNA in five lung carcinoma samples and the
presence of OCT4A mRNA in lung carcinoma cell line H460.
OCT4A is therefore no marker of cancer stem cell-ness in
N-GCT, despite its undisputed crucial role in physiological
(maintenance of) pluripotency (in germ cell precursors and their
malignant counterparts) (Pesce and Scholer, 2000, 2001). OCT4B1
does have a significant tendency toward specificity for the
pluripotent stem cell component of UNDIF-GCTs (Figures 2A
and B, Tables 2 and 3). It is however also (highly) expressed in
differentiated tumours and cell lines (Figures 2C and 3, Tables 2
and 3). OCT4B1 has been associated with detection of pluripotency
before, but no functional relation has been proven, and recent
research has functionally linked OCT4B1 to OCT4B (stress
response) rather than pluripotency (Gao et al, 2010).
CONCLUSION
This research confirms that different OCT4 isoforms (and pseudo-
genes) contribute to nonspecific findings of OCT3/4 expression in
various tissues and cell lines. This observation emphasises the
necessity of using highly specific primer sets and antibodies to
investigate the presence of expression of functional (nuclear) OCT3/4
(protein). The presented data confirms the specificity of OCT4A as a
marker for the seminomatous and the stem cell component of non-
seminomatous GCTs and illustrates the varying mRNA expression
levels of OCT3/4 isoforms in other types of solid cancer and cell lines.
OCT4A and OCT4B1 were both confirmed to have a significantly
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higher expression in tissues with a known stem cell component, but
until now, only OCT4A can be directly functionally linked to
pluripotency. Moreover, this study shows that OCT3/4 protein
detection is of crucial importance, because of clear discrepancies
between even isoform-specific mRNA expression and protein
detection, possibly due to post-transcriptonal regulation. A synergis-
tic role for the different OCT4 splice variants, possibly by competitive
miR binding, might be an interesting model to investigate.
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